Roles of lipid metabolism in keloid development

Lipids in Health and Disease

Rei Ogawa²  Chenyu Huang¹ 

[1] Department of Plastic Surgery, Meitan General Hospital, Beijing, China;Department of Plastic, Reconstructive and Aesthetic Surgery, Nippon Medical School, 1-1-5 Sendagi Bunkyo-ku, Tokyo, 113-8603, Japan

关键词: Mechanotransduction;    Inflammation;    Keloid;    Pathological scar;    Lipid metabolism;   

Others  :  834730
DOI  :  10.1186/1476-511X-12-60

 received in 2013-03-01, accepted in 2013-04-26,  发布年份 2013

【 摘 要 】

Keloids are common cutaneous pathological scars that are characterised by the histological accumulation of fibroblasts, collagen fibres, and clinically significant invasive growth. Although increasing lines of research on keloids have revealed genetic and environmental factors that contribute to their formation, the etiology of these scars remains unclear. Several studies have suggested the involvement of lipid metabolism, from a nutritional point of view. However, the role that lipid metabolism plays in the pathogenesis and progression of keloids has not previously been reviewed. The progress that has been made in understanding the roles of the pro- and anti-inflammatory lipid mediators in inflammation, and how they relate to the formation and progression of keloids, is also outlined. In particular, the possible relationships between mechanotransduction and lipid metabolites in keloids are explored. Mechanotransduction is the process by which physical forces are converted into biochemical signals that are then integrated into cellular responses. It is possible that lipid rafts and caveolae provide the location of lipid signaling and interactions between these signaling pathways and mechanotransduction. Moreover, interactions between lipid signaling pathway molecules and mechanotransduction molecules have been observed. A better understanding of the lipid profile changes and the functional roles lipid metabolism plays in keloids will help to identify target molecules for the development of novel interventions that can prevent, reduce, or even reverse pathological scar formation and/or progression.

【 授权许可】

   
2013 Huang and Ogawa; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Lee JY, Yang CC, Chao SC, Wong TW: Histopathological differential diagnosis of keloid and hypertrophic scar. Am J Dermatopathol 2004, 26:379-384.
• [2]Huang C, Akaishi S, Hyakusoku H, Ogawa R: Are keloid and hypertrophic scar different forms of the same disorder? A fibroproliferative skin disorder hypothesis based on keloid findings. Int Wound J 2012. [Epub ahead of print]
• [3]Marneros AG, Norris JE, Watanabe S, Reichenberger E, Olsen BR: Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11. J Invest Dermatol 2004, 122:1126-1132.
• [4]Ogawa R: Keloid and hypertrophic scarring may result from a mechanoreceptor or mechanosensitive nociceptor disorder. Med Hypotheses 2008, 71:493-500.
• [5]Fong EP, Bay BH: Keloids - the sebum hypothesis revisited. Med Hypotheses 2002, 58:264-269.
• [6]Akaishi S, Ogawa R, Hyakusoku H: Keloid and hypertrophic scar: neurogenic inflammation hypotheses. Med Hypotheses 2008, 71:32-38.
• [7]Louw L, Engelbrecht AM, Cloete F, van der Westhuizen JP, Dumas L: Impairment in the fatty acid composition of keloids. Adv Exp Med Biol 1997, 400B:905-910.
• [8]Louw L: Keloids in rural black South Africans. Part 1: general overview and essential fatty acid hypotheses for keloid formation and prevention. Prostaglandins Leukot Essent Fatty Acids 2000, 63:237-245.
• [9]Louw L, Dannhauser A: Keloids in rural black South Africans. Part 2: dietary fatty acid intake and total phospholipid fatty acid profile in the blood of keloid patients. Prostaglandins Leukot Essent Fatty Acids 2000, 63:247-253.
• [10]Louw L: Keloids in rural black South Africans. Part 3: a lipid model for the prevention and treatment of keloid formations. Prostaglandins Leukot Essent Fatty Acids 2000, 63:255-262.
• [11]Tachi M, Iwamori M: Mass spectrometric characterization of cholesterol esters and wax esters in epidermis of fetal, adult and keloidal human skin. Exp Dermatol 2008, 17:318-323.
• [12]Pochi PE: The pathogenesis and treatment of acne. Annu Rev Med 1990, 41:187-198.
• [13]Kao JS, Fluhr JW, Man MQ, Fowler AJ, Hachem JP, Crumrine D, Ahn SK, Brown BE, Elias PM, Feingold KR: Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003, 120:456-464.
• [14]Ogawa R, Okai K, Tokumura F, Mori K, Ohmori Y, Huang C, Hyakusoku H, Akaishi S: The relationship between skin stretching/contraction and pathologic scarring: the important role of mechanical forces in keloid generation. Wound Repair Regen 2012, 20:149-157.
• [15]Miles EA, Allen E, Calder PC: In vitro effects of eicosanoids derived from different 20-carbon Fattyacids on production of monocyte-derived cytokines in human whole blood cultures. Cytokine 2002, 20:215-223.
• [16]Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN: Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001, 2:612-619.
• [17]Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, Behbehani B, Colgan SP, Stahl GL, Merched A, Petasis NA, Chan L, Van Dyke TE: Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 2003, 171:6856-6865.
• [18]Yeh FL, Shen HD, Lin MW, Chang CY, Tai HY, Huang MH: Keloid-derived fibroblasts have a diminished capacity to produce prostaglandin E2. Burns 2006, 32:299-304.
• [19]Hayashi T, Nishihira J, Koyama Y, Sasaki S, Yamamoto Y: Decreased prostaglandin E2 production by inflammatory cytokine and lower expression of EP2 receptor result in increased collagen synthesis in keloid fibroblasts. J Invest Dermatol 2006, 126:990-997.
• [20]Sakaki H, Matsumiya T, Kusumi A, Imaizumi T, Satoh H, Yoshida H, Satoh K, Kimura H: Interleukin-1beta induces matrix metalloproteinase-1 expression in cultured human gingival fibroblasts: role of cyclooxygenase-2 and prostaglandin E2. Oral Dis 2004, 10:87-93.
• [21]Ueki S, Kato H, Kobayashi Y, Ito W, Adachi T, Nagase H, Ohta K, Kayaba H, Chihara J: Anti- and proinflammatory effects of 15-deoxy-delta-prostaglandin J2(15d-PGJ2) on human eosinophil functions. Int Arch Allergy Immunol 2007, 143(Suppl 1):15-22.
• [22]Babcock TA, Novak T, Ong E, Jho DH, Helton WS, Espat NJ: Modulation of lipopolysaccharide-stimulated macrophage tumor necrosis factor-alpha production by omega-3 fatty acid is associated with differential cyclooxygenase-2 protein expression and is independent of interleukin-10. J Surg Res 2002, 107:135-139.
• [23]De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr, Libby P: The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb 1994, 14:1829-1836.
• [24]Khalfoun B, Thibault F, Watier H, Bardos P, Lebranchu Y: Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. Adv Exp Med Biol 1997, 400B:589-597.
• [25]Datubo-Brown DD, Blight A: Inhibition of human fibroblast growth in vitro by a snake oil. Br J Plast Surg 1990, 43:183-186.
• [26]Kieran NE, Maderna P, Godson C: Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney Int 2004, 65:1145-1154.
• [27]Martins V, Valença SS, Farias-Filho FA, Molinaro R, Simões RL, Ferreira TP, e Silva PM, Hogaboam CM, Kunkel SL, Fierro IM, Canetti C, Benjamim CF: ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. J Immunol 2009, 182:5374-5381.
• [28]Krönke G, Reich N, Scholtysek C, Akhmetshina A, Uderhardt S, Zerr P, Palumbo K, Lang V, Dees C, Distler O, Schett G, Distler JH: The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. Ann Rheum Dis 2012, 71:1081-1087.
• [29]Börgeson E, Docherty NG, Murphy M, Rodgers K, Ryan A, O’Sullivan TP, Guiry PJ, Goldschmeding R, Higgins DF, Godson C: Lipoxin A₄ and benzo-lipoxin A₄ attenuate experimental renal fibrosis. FASEB J 2011, 25:2967-2979.
• [30]Serhan CN: Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 2007, 25:101-137.
• [31]Qu X, Zhang X, Yao J, Song J, Nikolic-Paterson DJ, Li J: Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation. J Pathol 2012. [Epub ahead of print]
• [32]Zhang G, Kazanietz MG, Blumberg PM, Hurley JH: Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester. Cell 1995, 81:917-924.
• [33]Preiss J, Loomis CR, Bishop WR, Stein R, Niedel JE, Bell RM: Quantitative measurement of sn-1,2-diacylglycerols present in platelets, hepatocytes, and ras- and sis-transformed normal rat kidney cells. J Biol Chem 1986, 261:8597-8600.
• [34]Tepper CG, Jayadev S, Liu B, Bielawska A, Wolff R, Yonehara S, Hannun YA, Seldin MF: Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity. Proc Natl Acad Sci U S A 1995, 92:8443-8447.
• [35]Jayadev S, Liu B, Bielawska AE, Lee JY, Nazaire F, Pushkareva MYu, Obeid LM, Hannun YA: Role for ceramide in cell cycle arrest. J Biol Chem 1995, 270:2047-2052.
• [36]Ishihara H, Yoshimoto H, Fujioka M, Murakami R, Hirano A, Fujii T, Ohtsuru A, Namba H, Yamashita S: Keloid fibroblasts resist ceramide-induced apoptosis by overexpression of insulin-like growth factor I receptor. J Invest Dermatol 2000, 115:1065-1071.
• [37]Lu F, Gao J, Ogawa R, Hyakusoku H, Ou C: Fas-mediated apoptotic signal transduction in keloid and hypertrophic scar. Plast Reconstr Surg 2007, 119:1714-1721.
• [38]Sellmayer A, Danesch U, Weber PC: Modulation of the expression of early genes by polyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 1997, 57:353-357.
• [39]Ogawa R, Akaishi S, Huang C, Dohi T, Aoki M, Omori Y, Koike S, Kobe K, Akimoto M, Hyakusoku H: Clinical applications of basic research that shows reducing skin tension could prevent and treat abnormal scarring: the importance of fascial/subcutaneous tensile reduction sutures and flap surgery for keloid and hypertrophic scar reconstruction. J Nihon Med Sch 2011, 78:68-76.
• [40]Huang H, Kamm RD, Lee RT: Cell mechanics and mechanotransduction: pathways, probes, and physiology. Am J Physiol Cell Physiol 2004, 287:C1-C11.
• [41]Ingber DE: Mechanobiology and diseases of mechanotransduction. Ann Med 2003, 35:564-577.
• [42]Huang C, Ogawa R: Fibroproliferative disorders and their mechanobiology. Connect Tissue Res 2012, 53:187-196.
• [43]Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000, 1:31-39.
• [44]Allen JA, Halverson-Tamboli RA, Rasenick MM: Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 2007, 8:128-140.
• [45]Ferraro JT, Daneshmand M, Bizios R, Rizzo V: Depletion of plasma membrane cholesterol dampens hydrostatic pressure and shear stress-induced mechanotransduction pathways in osteoblast cultures. Am J Physiol Cell Physiol 2004, 286:C831-C839.
• [46]Park H, Go YM, St John PL, Maland MC, Lisanti MP, Abrahamson DR, Jo H: Plasma membrane cholesterol is a key molecule in shear stress-dependent activation of extracellular signal-regulated kinase. J Biol Chem 1998, 273:32304-32311.
• [47]Radel C, Carlile-Klusacek M, Rizzo V: Participation of caveolae in beta1 integrin-mediated mechanotransduction. Biochem Biophys Res Commun 2007, 358:626-631.
• [48]Radel C, Rizzo V: Integrin mechanotransduction stimulates caveolin-1 phosphorylation and recruitment of Csk to mediate actin reorganization. Am J Physiol Heart Circ Physiol 2005, 288:H936-H945.
• [49]Zhang GY, Yu Q, Cheng T, Liao T, Nie CL, Wang AY, Zheng X, Xie XG, Albers AE, Gao WY: Role of caveolin-1 in the pathogenesis of tissue fibrosis by keloid-derived fibroblasts in vitro. Br J Dermatol 2011, 164:623-627.
• [50]Sandulache VC, Parekh A, Li-Korotky H, Dohar JE, Hebda PA: Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis. Wound Repair Regen 2007, 15:122-133.
• [51]Zhang GY, Cheng T, Luan Q, Liao T, Nie CL, Zheng X, Xie XG, Gao WY: Vitamin D: a novel therapeutic approach for keloid, an in vitro analysis. Br J Dermatol 2011, 164:729-737.
• [52]Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazono K, Kato S: Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999, 283:1317-1321.
• [53]Subramaniam N, Leong GM, Cock TA, Flanagan JL, Fong C, Eisman JA, Kouzmenko AP: Cross-talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem 2001, 276:15741-15746.
• [54]Blume-Peytavi U, Geilen CC, Sommer C, Almond-Roesler B, Orfanos CE: The phospholipid analogue hexadecylphosphocholine (HePC) inhibits proliferation of keloid fibroblasts in vitro and modulates their fibronectin and integrin synthesis. Arch Dermatol Res 1997, 289:164-169.